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Abstract  24 
Bats are implicated as the natural reservoirs for several highly pathogenic viruses that can 25 
infect other animal species, including man. Here, we investigate the potential for two 26 
recently discovered bat rubulaviruses, Achimota virus 1 (AchPV1) and Achimota virus 2 27 
(AchPV2), isolated from urine collected under urban bat (Eidolon helvum) roosts in 28 
Ghana, West Africa, to infect small laboratory animals. AchPV1 and AchPV2 are 29 
classified in the family Paramyxoviridae and cluster with other bat derived zoonotic 30 
rubulaviruses (i.e. Sosuga, Menangle and Tioman viruses). To assess the susceptibility of 31 
AchPV1 and AchPV2 in animals, infection studies were conducted in ferrets, guinea pigs 32 
and mice. Seroconversion, immunohistological evidence of infection, and viral shedding 33 
were identified in ferrets and guinea pigs, but not in mice. Infection was associated with 34 
respiratory disease in ferrets. Viral genome was detected in a range of tissues from ferrets 35 
and guinea pigs, however virus isolation was only achieved from ferret tissues. The 36 
results from this study indicate Achimota viruses (AchPVs) are able to cross the species 37 
barrier. Consequently, vigilance for infection with and disease caused by these viruses in 38 
people and domesticated animals is warranted in sub-Saharan Africa and the Arabian 39 
Peninsula where the reservoir hosts are present.  40 
 41 
 42 
 43 
 44 
 45 
 46 
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INTRODUCTION 47 
New and emerging viral infections impose a significant burden on human health and on 48 
the world economy. The majority of emerging infectious diseases affecting humans today 49 
are of animal origin with approximately three quarters arising from wildlife [1]. Bats 50 
have been shown to harbour more zoonotic viruses than other mammalian species [2 & 3] 51 
and are implicated in outbreaks of a number of highly pathogenic zoonotic viruses, 52 
including filoviruses, coronaviruses, paramyxoviruses and reoviruses. Ebola virus (EboV) 53 
RNA and antibodies have been discovered in African fruit bats [4]. The largest human 54 
outbreak of EboV occurred in West Africa in 2013-2014, resulting in nearly 30,000 55 
infections and 11,000 deaths and took over a year to contain [5]. SARS coronavirus 56 
emerged in China in 2002 and infected over 8000 people causing 774 deaths [6] and the 57 
MERS coronavirus continues to infect people and cause death in the Middle East [7]. 58 
Bats have since been found to harbour a multitude of coronaviruses closely related to 59 
SARS and MERS [8 & 9]. Pteropid bats are the reservoir hosts for the deadly 60 
henipaviruses, Nipah virus (NiV) and Hendra virus (HeV) [10 & 11]. NiV continues to 61 
cause fatal encephalitis in humans almost annually in Bangladesh, while HeV has spilled-62 
over into horses in Australia nearly every year since 2004 and has killed four people [12 63 
& 13]. Orthoreoviruses have been isolated from bats and humans in Southeast Asia where 64 
they have caused flu-like illness in people [14]. Known zoonotic viruses of bat origin 65 
continue to be of concern for human and animal health, and active surveillance provides 66 
our best option for monitoring these agents as well as identifying novel pathogens of 67 
zoonotic potential.   68 
 69 
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The recently discovered rubulaviruses, Achimota virus 1 and Achimota virus 2 (AchPV1 70 
and AchPV2), were isolated from bat (Eidolon helvum) urine samples collected beneath 71 
urban bat roosts in Ghana, West Africa [15]. AchPV1 and AchPV2 are newly recognised 72 
viral species in the family Paramyxoviridae, where they cluster with other bat 73 
rubulaviruses. Despite being discovered in the same study, the AchPVs are not nearest-74 
phylogenetic relatives and share only 31 to 64% protein amino acid identities [15]. Their 75 
relationship to each other is similar to their relationships with other bat rubulaviruses 76 
such as Sosuga (SosPV), Menangle (MenPV) and Tioman (TioPV) viruses (sharing 58-77 
70% N protein amino acid sequence identities), which have been shown to cause human 78 
infection. SosPV was isolated from a wildlife biologist studying bats and rodents in 79 
Africa in 2012 and is believed to be the causative agent for a severe flu-like illness and 80 
skin rash [16]. Follow up investigations revealed the presence of this virus in the spleen 81 
of Rousettus aegyptiacus bats [17]. MenPV first emerged in a piggery in NSW, Australia, 82 
in 1997 causing reproductive disease in pigs [18]. Two piggery workers had flu-like 83 
illness during the outbreak and were later found to have MenPV neutralising antibodies. 84 
Serological evidence of MenPV infection was also found in flying foxes roosting near the 85 
piggery and the virus was later isolated from Pteropus alecto urine [18 & 19]. TioPV was 86 
isolated from pteropid bat urine on Tioman Island in 2001 during the search for the 87 
reservoir host of Nipah virus [20]. It was later found that humans on the island had 88 
neutralising antibodies to TioPV, although no associated disease has been reported [21].  89 
 90 
Based on what is known of these closely related bat rubulaviruses, the potential of 91 
AchPV1 and AchPV2 to infect and cause disease in other species is worthy of further 92 
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investigation. Serological surveys of Eidolon helvum populations in Africa have been 93 
conducted for AchPVs and have shown a widespread presence of neutralising antibodies 94 
[15]. In addition, a survey of human sera collected from Ghana and Tanzania detected 95 
AchPV2 neutralising antibodies in three of 442 samples tested, however no neutralising 96 
antibodies to AchPV1 were detected in these sera. Two of the antibody positive samples 97 
were from healthy adults and one was from a febrile paediatric patient [15]. These data 98 
suggest that AchPV2 is zoonotic, but whether AchPV1 is zoonotic remains unknown.  99 
 100 
To further investigate the infection potential of AchPV1 and AchPV2, we conducted 101 
studies in three species of small laboratory animal; ferret (Mustela putorius furo), guinea 102 
pig (Cavia porcellus) and mouse (Mus musculus domesticus). First, we conducted 103 
observational studies to determine the susceptibility of these animals to infection by 104 
AchPV1 or AchPV2. Second, time course studies were performed using AchPV2 to 105 
obtain data on viral replication sites and potential routes of transmission.  106 
 107 
RESULTS  108 
Observational study with AchPV1 and AchPV2 in ferrets  109 
Two adult male ferrets aged 11 – 13 months were given 105 TCID50 AchPV1 oronasally 110 
in 1 ml of inoculum and another two adult male ferrets aged 11 – 13 months were given 111 
105 TCID50 AchPV2 oronasally in 1 ml of inoculum. The animals were observed daily for 112 
clinical signs and then electively euthanased at 21 days post challenge (pc). 113 
 114 
6 
 
One of the two ferrets exposed to AchPV1 remained clinically well and was electively 115 
euthanased at the end of experiment on day 21 pc. The other ferret showed signs of upper 116 
respiratory tract infection (sneezing, coughing) and weight loss from day 1 pc, and was 117 
euthanased at day 14 pc when it had reached a predetermined humane endpoint of 10 % 118 
bodyweight loss. Post mortem examination revealed a pleural effusion and 119 
bronchopneumonia of the right intermediate lung lobe. Each ferret developed neutralising 120 
antibody against AchPV1, with titres of 1:320 (healthy) and 1:80 (ill) (Table 1). 121 
 122 
One of two ferrets exposed to AchPV2 remained clinically well and was electively 123 
euthanased at the end of the experiment on day 21 pc. The other ferret maintained normal 124 
play activity but showed signs of upper respiratory tract infection (sneezing, purulent 125 
nasal discharge) from day 3 pc and which resolved by day 11 pc. The animal was 126 
electively euthanased at the end of the experiment on day 21 pc. Each ferret developed 127 
neutralising antibody against AchPV2, with titres > 1:1280 (healthy) and 1:1280 128 
(ill/recovered) (Table 1). 129 
 130 
In summary, it is unclear whether the signs of respiratory tract disease in one of two 131 
ferrets given either AchPV1 or AchPV2 were attributable to infection by the challenge 132 
virus or by co-infection of an unknown pathogen. As higher neutralising antibody titres 133 
were observed in ferrets infected with AchPV2, and as there was prior serological 134 
evidence of this virus in people, AchPV2 was selected for a time-course study with 135 
ferrets. 136 
 137 
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Observational study with AchPV1 and AchPV2 in guinea pigs  138 
Four adult female guinea pigs were given 105 TCID50 AchPV1 oronasally in 1 ml of 139 
inoculum and another four adult female guinea pigs were given 105 TCID50 AchPV2 140 
oronasally in 1 ml of inoculum. The animals were observed daily for clinical signs and 141 
then electively euthanased at 21 days pc. 142 
  143 
All four guinea pigs exposed to AchPV1 remained clinically well and were electively 144 
euthanased on day 21 pc. Each guinea pig developed neutralising antibody against 145 
AchPV1, with titres of 1:320, 1:80, 1:80 and 1:40 (Table 1). Similarly, all four guinea 146 
pigs exposed to AchPV2 remained clinically well and were electively euthanased on day 147 
21 pc. Each guinea pig developed neutralising antibody against AchPV2, with titres of 148 
1:320, 1:160, 1:80 and 1:40 (Table 1). 149 
 150 
Based on the same rationale as for ferrets, AchPV2 was selected for a time-course study 151 
with guinea pigs.  152 
 153 
Observational study with AchPV1 and AchPV2 in mice 154 
Ten mice (five female BALB/c mice aged 12 weeks and five female BALB/c mice aged 155 
over 12 months) were given 103 TCID50 AchPV1 intranasally in 50 µl of inoculum and 156 
another ten mice (five female BALB/c mice aged 12 weeks and five female BALB/c 157 
mice aged over 12 months) were given 103 TCID50 AchPV2 intranasally in 50 µl of 158 
inoculum. The animals were observed daily for clinical signs and then electively 159 
euthanased at 21 days pc.  160 
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 161 
All ten mice exposed to AchPV1 remained clinically well and were electively euthanased 162 
on day 21 pc. Neutralising antibody against AchPV1 was not detected in any mouse. 163 
Likewise, all ten mice exposed to AchPV2 remained clinically well and were electively 164 
euthanased on day 21 pc. Neutralising antibody against AchPV2 was not detected in any 165 
mouse. As mice had no detectable signs of disease and did not seroconvert to either 166 
AchPV1 or AchPV2, no further studies were conducted with mice.   167 
 168 
 Time course study with AchPV2 in ferrets  169 
1. Clinical and Pathological findings  170 
For this study, eight adult female ferrets were given 105 TCID50 AchPV2 oronasally in 1 171 
ml of inoculum and then two animals were pre-allocated for euthanasia on each of days 6, 172 
8, 10 and 21 pc. All eight ferrets in this study showed a mild but significant increase in 173 
rectal temperature over baseline on day 4 pc (p = 0.02), and a mild but significant loss of 174 
bodyweight compared to baseline on days 4 (p = 0.03) and 5 (p = 0.0004) pc 175 
(Supplementary Table S1 and S2). Otherwise, the animals remained clinically well until 176 
elective euthanasia, apart from one of two ferrets scheduled for euthanasia on day 8 pc. 177 
This ferret (#9) showed signs of upper respiratory tract infection (sneezing, serous and 178 
then purulent nasal discharge) between days 2 and 6 pc and was euthanased on humane 179 
grounds on day 6 pc following markedly decreased play activity. Other than ferret #9, no 180 
significant gross abnormalities were observed at post mortem examination in any of the 181 
ferrets.  182 
 183 
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The three ferrets euthanased on day 6 pc had minor histopathological changes associated 184 
with viral replication. Ferret #12 (day 6 pc) showed very mild acute bronchiolitis. 185 
Immunohistochemistry revealed viral antigen in germinal centres of the retropharyngeal 186 
lymph node but not in other tissues. In ferret #14 (day 6 pc), significant histopathological 187 
changes were confined to mild acute tonsillitis, and viral antigen was detected in the 188 
tonsillar and pharyngeal epithelium, retropharyngeal lymph node (particularly the 189 
parafollicular areas), bronchial epithelial cells, bronchus-associated lymphoid tissues 190 
(BALT), perivascular spindle cells in lung, and germinal centres and periarteriolar 191 
lymphoid sheaths of the spleen. In ferret #9, euthanased on day 6 pc with respiratory 192 
disease, there was moderately severe acute bronchiolitis, hyperplasia of the BALT, 193 
excess mucus production by bronchial glands, and focal lipoid pneumonia consistent with 194 
chronic bronchial disease. Post mortem examination of ferret #9 also revealed marked 195 
nodular hyperplasia of the liver with hepatic steatosis, but this lesion was considered to 196 
be unrelated to virus exposure as no AchPV2 viral antigen was detected in the liver. 197 
 198 
In ferret #9, AchPV2 viral antigen was identified in tonsillar and pharyngeal epithelium, 199 
germinal centres, parafollicular area and medulla of the retropharyngeal lymph node, 200 
tracheal epithelium, bronchial and bronchiolar epithelium (Figure 1), BALT and 201 
perivascular connective tissues of the lung, bronchial and mediastinal lymph node, 202 
periarteriolar lymphoid sheaths and red pulp of the spleen, mononuclear cells in the 203 
intestinal lamina propria and cells either within or lining the hepatic sinusoids.  204 
 205 
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In the single ferret euthanased on day 8 pc (ferret #16), there was mild focal acute 206 
tracheitis and bronchiolitis. The distribution of viral antigen was similar to ferret #9, with 207 
the addition of occasional bile duct epithelial cells and mononuclear cells of the portal 208 
triads, gut associated lymphoid tissue (GALT), and transitional epithelial cells in the 209 
bladder.  210 
 211 
The two ferrets euthanased on day 10 pc showed only small amounts of viral antigen by 212 
immunohistochemistry. Ferret #11 (day 10 pc) had mild focal acute bronchiolitis, and 213 
detection of viral antigen was limited to small amounts in tonsillar lymphoid tissue, 214 
bronchiolar epithelial cells, periarteriolar lymphoid sheaths of the spleen, and a diffuse 215 
scattering throughout the retropharyngeal lymph node. Ferret #13 (day 10 pc) also 216 
showed very mild acute bronchiolitis, with AchPV2 viral antigen confined to scattered 217 
gastric epithelial cells, GALT, and sparse deposits throughout tonsillar lymphoid tissue, 218 
bronchial and retropharyngeal lymph nodes.  219 
 220 
Of the two ferrets euthanased on day 21 pc, one (ferret #15) had very mild acute 221 
bronchiolitis and tracheitis and one had no detectable lesions. AchPV2 viral antigen was 222 
not detected in any tissue from either of these two ferrets. 223 
 224 
2. Detection of viral genomes 225 
AchPV2 RNA was detected by RT-qPCR in the oral swabs of 4 ferrets on day 2 pc and in 226 
all ferrets by day 4 pc until euthanasia: the highest levels were typically recorded on day 227 
6 or 8 pc (Table 2). Similar results were seen for the nasal washes: viral RNA was 228 
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detected in 3 ferrets on day 2 pc, and in all ferrets by day 4 pc until euthanasia, the 229 
highest levels typically were recorded on day 6 or 8 pc. Rectal swabs first detected 230 
AchPV2 on day 4 pc, when all ferrets were positive, the highest levels occurred on day 6 231 
or 8 pc. Viral RNA was commonly detected in blood samples from days 2 to 21 pc. 232 
Where viral RNA was found in successive blood samples from individual animals, 233 
highest levels were recorded on day 6 or 8 pc (Table 2).  234 
 235 
All tissue samples analysed from ferrets #9, #12 and #14 euthanased on day 6 pc were 236 
positive for viral RNA (data summarised in Figure 2), with the highest levels in bronchial 237 
and retropharyngeal lymph nodes and the lowest levels in heart, kidney and brain. Each 238 
tissue sample tested from ferret #16 (euthanased 8 days pc) was also positive for viral 239 
RNA, with the highest reading in retropharyngeal lymph node. On day 10 pc, ferrets #11 240 
and #13 exhibited generally similar distribution and quantities of viral RNA to the 241 
animals above. However, on day 21 pc the levels of viral RNA in ferrets #10 and #15 242 
were substantially lower, and largely limited to the retropharyngeal and bronchial lymph 243 
nodes and the spleen.  244 
 245 
3. Virus isolation 246 
Virus was reisolated from the nasal wash and from the oral and rectal swabs of ferret #9 247 
on day 6 pc, the nasal wash of ferret #10 on day 6 pc, the oral swab of ferret #11 on day 6 248 
pc, and from the oral swabs of ferret #16 on days 6 and 8 pc, plus the nasal wash of this 249 
ferret on day 8 pc (Table 2).  250 
 251 
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Virus was reisolated from ferrets killed on day 6 pc from tonsil, bronchial and 252 
retropharyngeal lymph nodes, lung and brain (ferret #9); trachea, tonsil, bronchial and 253 
retropharyngeal lymph nodes, and bladder (ferret #12); and tonsil and bronchial and 254 
retropharyngeal lymph nodes (ferret #14) (Figure 2). Virus was reisolated from tonsil and 255 
trachea of ferret #16 (which was killed on day 8 pc) and from the retropharyngeal lymph 256 
node and kidney of ferret #13 (day 10 pc), but not from ferret #11 (day 10 pc). Virus re-257 
isolation from ferrets killed on day 21 pc was limited to the retropharyngeal lymph node 258 
of ferret #15.  259 
 260 
4. Serology 261 
No neutralising antibodies were observed at day 2 or 4 pc but by day 6 low levels of 262 
neutralising antibodies were detected in the ferrets (Table 4). They showed an increase in 263 
neutralising antibody titre across the time points, with the animals bled at day 21 pc 264 
having neutralising antibody titres > 1:1280.  265 
 266 
Time course study with AchPV2 in guinea pigs 267 
1. Clinical and Pathological findings  268 
For this study, eight adult female guinea pigs were given 105 TCID50 AchPV2 oronasally 269 
in 1 ml of inoculum and then two animals were pre-allocated for euthanasia on each of 270 
days 6, 8, 10 and 21 pc. In guinea pigs, there were no significant differences in 271 
temperature or bodyweight over baseline up to day 6 pc, and the animals remained 272 
clinically healthy until elective euthanasia (Supplementary Table S3 and S4). No 273 
significant gross abnormalities were observed at post mortem examination, apart from 274 
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enlarged bronchial lymph nodes in one guinea pig euthanased on day 6 pc. The only 275 
histopathological changes observed were: mild acute tracheitis in all animals, two 276 
animals with mild acute bronchitis and/or bronchiolitis, and four with mild chronic 277 
interstitial pneumonia attributable to inhalation of plant material. In contrast to the 278 
observations in ferrets, the pattern of respiratory tract lesions did not correlate with the 279 
time post-exposure to AchPV2; very few histopathological changes were observed and all 280 
sections of tissues from all guinea pigs were negative for AchPV2 antigen by 281 
immunohistochemistry.  282 
 283 
2. Detection of viral genomes 284 
Low levels of AchPV2 were detected in the oral swab of one guinea pig on day 6 pc and 285 
of another on day 8 pc (Table 3). Rectal swabs were positive in four of six guinea pigs on 286 
day 8 pc, and from one guinea pig on day 10 pc. Viral RNA was found in the blood of 287 
one guinea pig on day 6 pc and of another on day 8 pc (both of which had viral RNA-288 
positive oral swabs at these times).  289 
 290 
Most tissue samples analysed from guinea pigs euthanased on day 6 and 8 pc were 291 
positive for viral RNA (data summarised in Figure 3), with highest levels present in nasal 292 
turbinates, bronchial and retropharyngeal lymph nodes, and spleen, and lower levels in 293 
trachea, lung, and liver. Detection of viral RNA was lowest and inconsistent from heart, 294 
kidney and brain. By day 10 pc, viral genome detection was limited to bronchial and/or 295 
retropharyngeal lymph nodes, lung, spleen, and nasal turbinates (one of two animals). On 296 
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day 21 pc, one guinea pig was negative by RT-qPCR for all tissues; in the other, viral 297 
genome was detected only in bronchial lymph node and spleen.  298 
 299 
3. Virus isolation 300 
Virus was not reisolated from any of the clinical samples, including those that were 301 
positive by AchPV2-specific RT-qPCR (Table 3). In addition, virus was not reisolated 302 
from any tissue sample, including those that were positive by AchPV2-specific RT-qPCR 303 
(Figure 3). 304 
 305 
4. Serology 306 
No neutralising antibodies were observed at day 2 or 4 pc but by day 6 low levels of 307 
neutralising antibodies were detected in the guinea pigs (Table 4). There was a slight 308 
increase in neutralising antibody titre across the time points with a titre of 1:160 by day 309 
21 pc.  310 
 311 
DISCUSSION 312 
We investigated the potential of the two recently discovered bat rubulaviruses, AchPV1 313 
and AchPV2, to infect laboratory animals representing three species (ferret, guinea pig 314 
and mouse). Seroconversion to both Achimota viruses in ferrets and guinea pigs indicated 315 
these animals were susceptible to infection, however mice did not seroconvert to either 316 
virus. Due to their body size, mice were given a lower dose of inoculum, and were 317 
challenged intranasally, rather than via the oronasal route used for the ferrets and guinea 318 
pigs. The difference in volume and inoculation route may account for the lack of 319 
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seroconversion seen in the mice, however it is probably more likely that this species is 320 
resistant to infection. Higher levels of neutralising antibodies were observed in the ferrets 321 
and guinea pigs infected with AchPV2 compared to those infected with AchPV1. This 322 
result reflected in vitro data where it was observed previously that AchPV2 consistently 323 
grows to a higher titre than AchPV1 in vero and PaKi cell lines [15]. Additionally, 324 
respiratory tract disease in one of two ferrets given either AchPV1 or AchPV2 was seen 325 
in the observational studies, although it remains unclear if this was related to Achimota 326 
virus infection or was entirely due to co-infection by an unknown pathogen. AchPV2 was 327 
chosen for a time-course study based on two criteria: higher neutralising antibodies 328 
observed in ferrets and guinea pigs compared to AchPV1, and previous evidence of 329 
human infection (AchPV2 neutralising antibodies). Given more time and resources, it 330 
would be worthwhile to do an additional time course study with AchPV1, to further 331 
investigate the differences between these two viruses. 332 
 333 
The AchPV2 time-course studies provided additional evidence that this virus can infect 334 
ferrets and guinea pigs and revealed viral replication sites and potential routes of 335 
transmission. Evidence of infection was supported by virus re-isolation from clinical 336 
specimens and post-mortem tissue samples, and viral antigen detection in tissues by 337 
quantitative real-time PCR and immunohistochemistry. Although there was evidence of 338 
mild malaise in infected ferrets (raised body temperature and weight loss), a distinct 339 
clinical syndrome with specific clinical signs was not identified in either ferrets or guinea 340 
pigs. Moreover, no histological lesions were attributed with confidence to infection by 341 
AchPV2. Mild tonsillitis, tracheitis and bronchiolitis were recorded in ferrets, but in some 342 
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animals the lesions were identified without evidence of specific association with AchPV2 343 
antigen. The ferrets were sourced from a colony free of influenza and canine distemper 344 
virus, were clinically healthy at the time of exposure to AchPV2, and were not 345 
maintained on a particulate substrate. The pathogenesis of these legions remains 346 
uncertain, although an opportunistic bacterial or other viral aetiology could not be 347 
excluded. In other tissues, such as bile duct epithelium and transitional epithelial cells of 348 
the bladder, viral antigen was seen without substantial inflammatory reaction or tissue 349 
injury.  350 
 351 
For ferrets, following an incubation period of 5 to 6 days, AchPV2 was shed in oral and 352 
nasal secretions and the development of virus neutralising antibody was generally 353 
associated with virus clearance. The results of quantitative real-time PCR, virus re-354 
isolation and immunohistochemistry taken together identified the major sites of AchPV2 355 
replication in ferrets to be respiratory tract epithelium and associated lymphoid tissues. 356 
Virus was able to be re-isolated from all of the ferrets at all time points from at least one 357 
tissue or clinical sample (swab or nasal wash) but not from blood. Although virus was not 358 
re-isolated from blood, the development of viremia may be inferred by confirmation of 359 
infection within spleen and urinary tract epithelium by immunohistochemistry and viral 360 
genome detection in the blood by quantitative real-time PCR. In the absence of other 361 
clinico-pathological support for CNS infection, virus in blood may also account for the 362 
re-isolation of AchPV2 from one sample of ferret brain tissue.  363 
 364 
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Although exposure to AchPV2 resulted in production of neutralising antibodies in guinea 365 
pigs, antibody titres were much lower than for the ferrets. Significantly, patterns of viral 366 
RNA detection  from guinea pigs were generally similar to those in ferrets, but virus was 367 
not re-isolated from any tissue or clinical sample from guinea pigs and viral antigen was 368 
not demonstrated in their tissues by immunohistochemistry. The sites of AchPV2 369 
replication in guinea pigs, therefore, could not be determined with confidence. Our 370 
observations suggest that guinea pigs are less permissive to AchPV2 infection than 371 
ferrets.   372 
 373 
When assessing the spill-over potential and working up an animal model for a novel 374 
virus, it is important to use animals from more than one species. There is no reliable 375 
method to determine the best species simply by characterising the virus, which is a big 376 
limitation of using virus discovery as a stand-alone surveillance strategy for zoonotic 377 
pathogen discovery. Therefore, it is only possible to do what is practical and feasible in 378 
terms of assessing potential spill-over hosts. Small laboratory animals such as ferrets, 379 
guinea pigs and mice, representing different mammalian orders or families, offer the most 380 
practical advantages for testing spill-over potential and, in this study, were a panel that 381 
demonstrated discriminatory power for the infection potential of the novel viruses tested. 382 
 383 
The continued search for novel viruses in wildlife species, particularly in regions of the 384 
world where encroachment of humans and livestock into wildlife habitats is increasing, 385 
such as sub-Saharan Africa, is imperative if we are going to be able to identify disease in 386 
these regions caused by novel pathogens. New discoveries of wildlife viruses alone, 387 
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however, will not inform risks to livestock or public health. Viral phylogeny and other 388 
signals of spill-over potential, such as the serosurveillance results that guided this study, 389 
are required to identify potential new health threats [22]. The Achimota viruses described 390 
in this paper demonstrate ability to cross the species barrier and may be causing 391 
undiagnosed disease in domesticated animals and humans within the wide geographical 392 
range of the bat reservoir species, Eidolon helvum.   393 
 394 
MATERIALS AND METHODS  395 
Animals, accommodation, handling and biosafety 396 
Ferrets were acquired from a colony free of infection by influenza H1 and H3 subtypes. 397 
Two male ferrets aged 11 – 13 months, four female guinea pigs, five female BALB/c 398 
mice aged 12 wks, and five female BALB/c mice aged over 12 months were used in each 399 
of the AchPV1 and AchPV2 observational studies. Eight female ferrets and eight female 400 
guinea pigs were used for the AchPV2 time course study. The animal husbandry methods 401 
and experimental design were approved by the CSIRO Australian Animal Health 402 
Laboratory’s Animal Ethics Committee (approvals AEC 1608 and AEC 1621) and were 403 
carried out in accordance with the relevant guidelines and regulations. Animals were 404 
housed at Biosafety Level 3 (BSL-3) in conventional caging systems to facilitate the 405 
expression and monitoring of natural behaviours, given complete premium dry food 406 
appropriate to the species, dietary treats, and provided with water ad libitum. Room 407 
temperature was maintained at 22oC with 15 air changes per hour and humidity varied 408 
between 40 and 60%. Before any manipulation occurred, such as exposure to virus, 409 
collection of clinical samples, or euthanasia, animals were immobilised with a mixture of 410 
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ketamine HCl (Ketamil®: 5 mg/kg in ferrets, 16mg/kg in guinea pigs, 75mg/kg in mice) 411 
and medetomidine (Domitor®: 50 µg/kg in ferrets, 20 µg/kg in guinea pigs, 1mg/kg in 412 
mice) by intramuscular or intraperitoneal (mice) injection. Where indicated, reversal was 413 
achieved with atipamazole (Antisedan®) administered by intramuscular (ferrets) or 414 
intraperitoneal (guinea pigs and mice) injection at 50 % of the medetomidine volume. All 415 
animals were implanted subcutaneously with temperature-sensing microchips 416 
(Lifechip®). Staff wore powered air purifying respirators, coveralls, impervious gloves 417 
and boots while in animal rooms. 418 
 419 
Animal infections and sampling 420 
For the observational studies, animals were exposed to either AchPV1 or AchPV2, 421 
previously isolated, grown and titrated in vero cells. Animal inoculation stocks were 422 
prepared as follows: after initial virus isolation, a parent stock of each virus was grown in 423 
vero cells. These parent stocks were then purified by three rounds of limiting dilution in 424 
vero cells. Finally, an animal inoculation stock was prepared from the third limiting 425 
dilution, resulting in a passage number of 6 times in vero cells from original isolation. 426 
The sequence of the animal inoculation stock was not compared to the original sequence 427 
of the isolated virus. Ferrets and guinea pigs were given 105 TCID50 oronasally in 1 ml of 428 
inoculum (500 µl oral and 500 µl nasal), and mice were given 103 TCID50 intranasally in 429 
50 µl of inoculum. General clinical observations were documented daily prior to as well 430 
as post challenge (pc). Animals were weighed and their temperatures recorded daily. 431 
Animals were euthanased at either a predetermined humane endpoint or 21 days pc. 432 
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Blood was collected for serology prior to virus exposure and at euthanasia. Tissues were 433 
not collected for the observational studies. 434 
 435 
For the subsequent time course studies, ferrets and guinea pigs were exposed oronasally 436 
to 105 TCID50 AchPV2, prepared as described above, in 1 ml of inoculum (500 µl oral 437 
and 500 µl nasal). Two animals were pre-allocated for euthanasia on each of days 6, 8, 10 438 
and 21 pc.  Nasal washes (ferrets only), oral and rectal swabs and blood samples, both in 439 
EDTA and for serum preparation, were collected from all available animals at days 2, 4, 440 
6, 8, 10 and 21 pc. Clinical samples were collected into tubes containing PBS with 441 
antibiotic-antimycotic (Invitrogen) for virus isolation and into tubes containing MagMAX 442 
viral lysis buffer (Ambion) for RNA extraction. While under anaesthesia, rectal 443 
temperatures of ferrets were recorded by digital thermometer.    444 
 445 
At post mortem examination of animals used for the AchPV2 time course study, the 446 
following tissues were collected for histology, immunohistochemistry, viral genome 447 
detection and virus isolation: nasal turbinates, tonsil, retropharyngeal lymph node, 448 
trachea, lung, hilar lymph node, bronchial lymph node, spleen, heart, kidney, liver, 449 
bladder and brain. Stomach, small and large intestine, pancreas, adrenal gland, ovary and 450 
uterus were also collected for histology and immunohistochemistry. Tissues were 451 
collected into tubes containing either neutral buffered 10% formalin (for histology and 452 
immunohistochemistry) or PBS plus antibiotic-antimycotic (Invitrogen) and 453 
homogenisation beads, homogenised using a bead beater, and clarified by centrifugation 454 
(for virus isolation or viral RNA detection).  455 
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 456 
RNA extraction and Reverse Transcriptase-quantitative Polymerase Chain Reaction  457 
For viral genome detection, RNA was extracted from tissue, blood and swab samples 458 
using the MagMAX viral RNA isolation kit (Ambion) following the manufacturers 459 
guidelines. A novel Reverse Transcriptase-quantitative Polymerase Chain Reaction (RT-460 
qPCR), was designed that specifically targets the nucleoprotein gene (N-gene) of 461 
AchPV2. For the design process, the N-gene sequence of AchPV2 (JX051320), as well as 462 
other closely related paramyxoviruses including SosPV, MenPV and TioPV, was 463 
retrieved from GenBank. Subsequently, sequence alignments were performed using 464 
Geneious software (Version 8.1, Biomatters). Potential primer and probe regions 465 
distinctive of AchPV2 were identified from these alignments and candidate primers and 466 
probes assessed using the Primer Express 3.0.1 program (Thermofisher-Applied 467 
Biosystems). An assay spanning the 625-700 nucleotide region (75 nucleotides in length) 468 
of the N-gene of AchPV2 (JX051320), consists of forward primer: D-715 (5’-469 
GCAGGTCTGGATCACAGTATGC -3’), reverse primer D-716 (5’-470 
TGCCAGTCGCCTCTCATCT -3’), and probe 471 
D-717 (5’ [FAM]-TGCATGACAGCATATGATCAGCCCACT-[BHQ-1]-3’. The 472 
optimized primer and probe concentrations and assay conditions were as follows: forward 473 
primer (D-715) and reverse primer (D-716): 300 nM, probe (D-716): 200 nM. Reactions 474 
were performed using AgPath-ID One-Step RT-PCR Kit (Thermofisher-Ambion) on an 475 
AB7500 Fast instrument using the thermal cycle: 1 cycle of 45 °C 10 min, 95 °C 10 min 476 
followed by 45 cycles of 95 °C 15 sec, 60 °C 45 sec. To determine the assay efficiency, a 477 
standard curve was generated using ten-fold serial dilutions of AchPV2 RNA and was 478 
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found to be 95%. The analytical specificity was investigated using a range of available 479 
paramyxoviruses, namely Newcastle disease virus, J virus, HeV, NiV and closely related 480 
rubulaviruses (MenPV and TioPV) and only the reference AchPV2 was detected by the 481 
RT-qPCR. For interpretation of results duplicate samples producing an average cycle 482 
threshold (Ct) less than 38 were considered positive. 483 
 484 
Virus isolation 485 
Vero cell monolayers were grown in 96 well tissue culture plates to 80 % confluency in 486 
cell media (Minimal Essential Medium containing Earle’s salts and supplemented with 2 487 
mM glutamine, antibiotic-antimycotic and 10 % fetal calf serum). 488 
Swab media and blood were serially diluted 10 fold and 50 µl added to each well. 489 
Supernatant from centrifuged tissue homogenate was serially diluted 10 fold and 50 µl 490 
added to each well. Vero cell monolayers were observed for viral CPE seven days post 491 
infection.  492 
 493 
Serology 494 
Serum was collected prior to viral challenge and again at euthanasia, and tested using a 495 
standard virus neutralisation test. Serial two-fold dilutions of test sera were prepared in 496 
duplicate in a 96-well tissue culture plate in 50 µL cell media (Minimal Essential 497 
Medium containing Earle’s salts and supplemented with 2 mM glutamine, antibiotic-498 
antimycotic and 10 % fetal calf serum). An equal volume of either AchPV1 or AchPV2 499 
working stock containing 200 TCID50 was added and the virus-sera mix incubated for 30 500 
min at 37 ºC in a humidified 5 % CO2 incubator. 100 µL of Vero cell suspension 501 
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containing 2 x 105 cells/mL was added and the plate incubated at 37 ºC in a humidified 5 502 
% CO2 incubator. The plate was observed for viral CPE after seven days and the serum 503 
neutralisation titre determined as being the dilution where 100% neutralisation was 504 
observed in duplicate wells. Serum samples that showed no neutralisation of virus in 505 
duplicate wells at the starting dilution (1:10) were described as negative.   506 
 507 
Histology and immunohistochemistry 508 
Formalin-fixed tissues were processed into paraffin wax and prepared into 4 µm thick 509 
sections using routine histological methods. For immunohistochemistry, antigen retrieval 510 
was performed using the DAKO PT LINK machine (Dako, Glostrup, Denmark) by 511 
heating the tissue sections to 97 oC for 30 minutes and then cooling to 70 oC in the 512 
Envision Flex Target high pH retrieval solution (DAKO) and washing for 5 minutes in 513 
Tris Buffer. After this, endogenous peroxidases were quenched by the addition of 3 % 514 
H2O2 solution. Tissue sections were then incubated with the primary antibody, polyclonal 515 
rabbit antisera raised against AchPV2, at a dilution of 1:2000. The visualization system 516 
used was Envision FLEX /horseradish peroxidase (HRP) conjugated with 3-Amino-9-517 
Ethylcarbazole (AEC) chromogen (DAKO AEC + substrate chromagen K3469). Slides 518 
were then counterstained with Lillie-Mayer haematoxylin (Australian Biostain, 519 
Traralgon, Australia) and Scotts tap water before mounting. A duplicate set of tissue 520 
sections were stained with hematoxylin and eosin stain for histological examination using 521 
routine methods. 522 
  523 
Statistical analysis 524 
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In the time-course study, bodyweights and rectal temperatures of ferrets, and 525 
bodyweights and microchip temperatures of guinea pigs, up to and including day 6 pc 526 
were compared using a repeated measures ANOVA followed by Dunnett’s multiple 527 
comparisons test (GraphPad Prism 7.02).  528 
 529 
Data availability 530 
The datasets generated during and/or analysed during the current study are available from 531 
the corresponding author on reasonable request. 532 
 533 
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Figures 640 
 641 
Figure 1. Viral antigen in bronchiolar epithelial cells and BALT in ferret #9 (polyclonal 642 
rabbit anti-AchPV2): note also intraluminal acute inflammatory infiltrate, of uncertain 643 
pathogenic significance.   644 
 645 
30 
 
Figure 2. Analysis of virus infection in ferrets by RNA detection and virus isolation. 646 
Average cycle threshold (Ct) values were obtained from testing tissues from AchPV2 647 
ferrets using RT-qPCR. Stars indicate samples that AchPV2 was re-isolated from. 648 
 649 
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 651 
 652 
 653 
 654 
 655 
 656 
 657 
 658 
 659 
 660 
 661 
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Figure 3. Analysis of virus infection in guinea pigs by RNA detection and virus isolation. 662 
Average cycle threshold (Ct) values were obtained from testing tissues from AchPV2 663 
guinea pigs using RT-qPCR. AchPV2 was unable to be re-isolated from any sample. 664 
 665 
 666 
 667 
 668 
 669 
 670 
 671 
 672 
 673 
 674 
 675 
 676 
 677 
 678 
 679 
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Tables 680 
 681 
Table 1. The serum neutralisation titres against AchPV1 and AchPV2 for ferret and 682 
guinea pig serum collected 21 days pc. The serum collected from the animals pre-683 
challenge (day 0) were all negative. Mouse sera were also tested but the data is not shown 684 
as they didn’t seroconvert. 685 
AchPV1 AchPV2 
Animal SNT Titre Animal SNT Titre 
Ferret 1 1:320 Ferret 1 >1:1280 
Ferret 2* 1:80 Ferret 2 1:1280 
Guinea Pig 1 1:40 Guinea Pig 1 1:160 
Guinea Pig 2 1:80 Guinea Pig 2 1:40 
Guinea Pig 3 1:320 Guinea Pig 3 1:80 
Guinea Pig 4 1:80 Guinea Pig 4 1:320 
*This animal became ill and was euthanized at day 14 pc instead of day 21 pc. 686 
 687 
 688 
 689 
 690 
 691 
Table 2. Analysis of viral shedding and viraemia in ferrets by RNA detection and virus 692 
isolation. Average cycle threshold (Ct) values were obtained from testing oral and rectal 693 
swabs, nasal washes and blood from AchPV2 ferrets using RT-qPCR.  694 
KEY: - indicates sample was negative (Av Ct >38); NA indicates sample was unavailable 695 
for testing; * indicates virus re-isolated at neat dilution; ** indicates virus re-isolated at 696 
1:5 dilution and *** indicates virus re-isolated at 1:50 dilution   697 
 698 
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  Days Post Challenge 
  Sample 0 2 4 6 8 10 21 
Ferret 
9 
Oral Swab - - 32.9 24.4 ***       
Rectal swab - - 34.1 24.9 **       
Nasal wash - 36.8 33 26 ***       
Blood - - NA 31.5       
Ferret 
12 
Oral Swab - - 32.10 21.8       
Rectal swab - - 29.50 22.6       
Nasal wash - - 31.40 25.1       
Blood - 35.9 26.50 NA       
Ferret 
14 
Oral Swab - 36.9 31.90 33       
Rectal swab - - 32.20 24.8       
Nasal wash - - 31.40 27.1       
Blood - 37.8 29.10 28.7       
Ferret 
16 
Oral Swab - 34.5 32.50 22.2 * 24 *     
Rectal swab - - 32.00 22.6 23     
Nasal wash - - 34.10 28.3 27 **     
Blood - - 31.30 30.1 20.9     
Ferret 
13 
Oral Swab - 36 31.50 23.5 24 23.60   
Rectal swab - - 29.50 22.8 23.4 23.70   
Nasal wash - - 33.60 25.9 22.3 24.50   
Blood - - 29.40 29.2 30.8 34.00   
Ferret 
11 
Oral Swab - - 31.9 22.9 *** 22 25.30   
Rectal swab - - 30.9 22 19.6 25.50   
Nasal wash - - 32.00 24.8 22.8 25.00   
Blood - - 28.90 NA 27.3 36.10   
Ferret 
15 
Oral Swab - 35 32.90 25.8 20.9 26.50 30 
Rectal swab - - 31.30 23.2 22.5 23.70 29 
Nasal wash - 34.3 34.20 26.3 25 25.30 30.5 
Blood - - 24.70 NA 24 36.00 30 
Ferret 
10 
Oral Swab - - 30.5 30.3 23.3 27.00 31.2 
Rectal swab - - 29 23.6 22.4 27.00 32.5 
Nasal wash - 37 31.9 25.3 ** 24.6 26.30 28.5 
Blood - - - NA NA 33.80 - 
 699 
 700 
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Table 3. Analysis of viral shedding and viraemia in guinea pigs by RNA detection and 701 
virus isolation. Average cycle threshold (Ct) values were obtained from testing oral and 702 
rectal swabs and blood from AchPV2 guinea pigs using RT-qPCR. AchPV2 was unable 703 
to be re-isolated from any sample.  704 
KEY: - indicates sample was negative (Av Ct >38)  705 
  Days Post Challenge 
  Sample 0 2 4 6 8 10 21 
Guinea 
Pig 1 
Oral Swab - - - -       
Rectal swab - - - -       
Blood - - - -       
Guinea 
Pig 2 
Oral Swab - - - 37.74       
Rectal swab - - - -       
Blood - - - 35.25       
Guinea 
Pig 3 
Oral Swab - - - - 36.44     
Rectal swab - - - - 35.09     
Blood - - - - 34.71     
Guinea 
Pig 4 
Oral Swab - - - - -     
Rectal swab - - - - 37.31     
Blood - - - - -     
Guinea 
Pig 5 
Oral Swab - - - - - -   
Rectal swab - - - - - -   
Blood - - - - - -   
Guinea 
Pig 6 
Oral Swab - - - - - -   
Rectal swab - - - - - -   
Blood - - - - -     
Guinea 
Pig 7 
Oral Swab - - - - - - - 
Rectal swab - - - - 35.39 34.97 - 
Blood - - - - - - - 
Guinea 
Pig 8 
Oral Swab - - - - - - - 
Rectal swab - - - - 33.98 - - 
Blood - - - - - - - 
 706 
 707 
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Table 4. The serum neutralisation titres against AchPV2 for ferret and guinea pig serum 708 
collected on days 6, 8, 10 and 21 pc. Sera collected on day 2 and 4 pc were also tested but 709 
were negative for neutralising antibodies (data not shown). 710 
Animal 
SNT 
Titre 
Animal 
SNT 
Titre 
Ferret 9* (Day6) 1:20 G.Pig 1 (Day6) 1:20 
Ferret 12 (Day6) 1:40 G.pig 2 (Day6) 1:20 
Ferret 14 (Day6) 1:640 G.Pig 3 (Day8) 1:20 
Ferret 16 (Day8) 1:640 G.pig 4 (Day8) 1:20 
Ferret 11 (Day10) 1:640 G.Pig 5 (Day10) 1:40 
Ferret 13 (Day10) >1:1280 G.pig 6 (Day10) 1:40 
Ferret 10 (Day21) >1:1280 G.Pig 7 (Day21) 1:160 
Ferret 15 (Day21) >1:1280 G.pig 8 (Day21) 1:160 
*This animal became ill and was euthanized at day 6 pc instead of day 8 pc 711 
 712 
  713 
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Supplementary Information 714 
  715 
 716 
Table S1: Rectal temperatures (°C) for ferrets post challenge 717 
    
Ferret # Day 0 Day 2 Day 4 Day 6 
9 39.3 38.7 39.7 39 
10 38.6 39.8 39.3 39.6 
11 38.8 39.1 39.5 39.7 
12 39.7 39.8 40.6 40.3 
13 38.5 40.5 40.2 40.4 
14 39.9 40.7 40.5 40.1 
15 38.9 39.5 39.1 39.5 
16 39.7 40.9 40.5 40.1 
 718 
 719 
 720 
Table S2: Bodyweights (g) for ferrets post challenge 721 
       
Ferret # Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 
9 772 770 748 750 725 730 680 
10 775 755 750 740 719 740 738 
11 965 950 980 940 930 940 925 
12 771 800 782 780 777 760 769 
13 1036 1040 1042 1040 1029 1000 1006 
14 1021 1015 1028 1010 1002 1000 1007 
15 954 945 950 950 930 930 941 
16 881 870 890 860 839 850 853 
 722 
 723 
 724 
Table S3: Microchip temperatures (°C) for guinea pigs post challenge 725 
     
G.Pig # Day 1 Day 2 Day 4 Day 5 Day 6 
1 38.5 37.7 38.4 38.1 39.8 
2 39 38.1 37.9 37.4 38.1 
3 37.6 38.3 38.3 38 38.8 
4 38.4 38.8 38.9 38.2 38.4 
5 38.1 38.9 38.4 38.1 38.5 
6 39.3 39.2 39.2 38.9 39 
7 38 38.6 38 38.2 38.4 
8 39 38.8 38.8 37.7 38.3 
37 
 
Table S4: Bodyweights (g) for guinea pigs post challenge 726 
       
G.Pig# Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 
1 568 552 554 560 573 584 590 
2 557 586 588 585 588 596 602 
3 595 565 618 621 617 639 635 
4 687 656 669 670 676 687 685 
5 679 649 662 666 672 684 686 
6 681 664 672 683 662 672 668 
7 675 669 683 669 670 689 693 
8 708 673 677 687 681 685 682 
 727 
 728 
 729 
 730 
 731 
Statistical analysis 732 
In the time-course study, bodyweights and rectal temperatures of ferrets, and 733 
bodyweights and microchip temperatures of guinea pigs, up to and including day 6 pc 734 
were compared using a repeated measures ANOVA followed by Dunnett’s multiple 735 
comparisons test (GraphPad Prism 7.02). 736 
 737 
 738 
 739 
 740 
